Of greater therapeutic relevance, MSK-ACCESS identified oncogenic targetable driver mutations and amplifications in EGFR, KRAS, MET, ERBB2, and BRAF. Characteristically, lung cancer samples lacking known mitogenic drivers by MSK-ACCESS were found to harbor STK11 and KEAP1 mutations. Here, EGFR is linked to lung cancer.